Panagiota Poziou

Dr. Panagiota Poziou

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
MFMatthew Falagas
Matthew Falagas
CAChristina Maria Asimotou
Christina Maria Asimotou
DKDimitrios S. Kontogiannis
Dimitrios S. Kontogiannis
LRLaura Terpsithea Romanos
Laura Terpsithea Romanos
PPPanagiota Poziou
Panagiota Poziou
ITIva D. Tzvetanova
Iva D. Tzvetanova
Tebipenem is a new carbapenem antibiotic that binds to penicillin-binding proteins (PBPs). Given the need for effective antibiotics against multidrug-resistant (MDR) bacteria, this review evaluated the in vitro antimicrobial activity of tebipenem against Gram-negative and Gram-positive bacteria, focusing on uropathogens. Five resources (Google Scholar, Web of Science, Embase, Scopus, and PubMed) were used to identify relevant articles. Of the 1322 articles identified, 9 relevant studies were included, which evaluated 12,501 Gram-negative and 122 Gram-positive pathogens. All nine studies (100%) assessed the activity of tebipenem against Escherichia coli, with an MIC90 value range of 0.015–>4 mg/L. Seven studies (77.8%) included Klebsiella pneumoniae, with an MIC90 value range of 0.015–0.5 mg/L. Six studies (66.7%) reported data on Proteus mirabilis, with an MIC90 value range of ≤0.125–0.5 mg/L. Two studies (22.2%) evaluated the activity of tebipenem against Enterococcus faecalis, with MIC90 of 1 mg/L among vancomycin-susceptible isolates and 32 mg/L in isolates with not-reported mechanisms of resistance. Two studies (22.2%) evaluated the activity of tebipenem against Enterococcus faecium, with MIC90 of >4 mg/L among both vancomycin-susceptible and vancomycin-resistant isolates and MIC90 of 128 mg/L among isolates with no resistance mechanism reported. Tebipenem demonstrated good activity against Enterobacterales, such as E. coli and K. pneumoniae. The antimicrobial agent exhibited higher MICs and a higher proportion of resistance among P. mirabilis isolates. Tebipenem could be effective for outpatient treatment of infections caused by MDR Gram-negative pathogens. However, given its potential to exert selective pressure for the development of antimicrobial resistance, it should be considered for patients with cUTIs when none of the first-line treatment options demonstrate in vitro antimicrobial activity.

17 September 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
MFMatthew Falagas
Matthew Falagas
CAChristina Maria Asimotou
Christina Maria Asimotou
DKDimitrios S. Kontogiannis
Dimitrios S. Kontogiannis
LRLaura Terpsithea Romanos
Laura Terpsithea Romanos
PPPanagiota Poziou
Panagiota Poziou
ITIva D. Tzvetanova
Iva D. Tzvetanova
Due to an oversight by the Editorial Office, Figure 1 in the original publication